Company profile
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Tegoprubart | phase2 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06126380 | phase2 | enrolling_by_invitation | 2023-10-25 | 2029-12-01 | Eledon Pharmaceuticals | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients |
| NCT05125068 | phase2 | terminated | 2022-03-21 | 2023-07-31 | Eledon Pharmaceuticals | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) |
| NCT05983770 | phase2 | completed | 2023-08-30 | 2025-09-11 | Eledon Pharmaceuticals | Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation |
| NCT05027906 | phase1_2 | recruiting | 2022-02-18 | 2027-01-01 | Eledon Pharmaceuticals | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant |
| NCT05480657 | phase1_2 | withdrawn | 2022-09-30 | 2024-08-01 | Eledon Pharmaceuticals | Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D |
FDA applications (0)
No records yet.